Natco Pharma Ltd announced on Wednesday that its Canadian subsidiary has invested USD 8 million (approximately Rs 70 crore) in U.S.-based biotechnology company eGenesis, Inc. The investment was made through Natco Pharma (Canada) Inc.
eGenesis, Inc. is a leading player in the field of xenotransplantation, working to develop human-compatible organs for transplant. The company aims to address the global organ shortage and improve treatment options for organ failure.
Natco Pharma’s Vice Chairman and CEO, Rajeev Nannapaneni, expressed the company’s belief in eGenesis’s vision, stating that xenotransplantation technology could potentially eliminate waitlist mortality and transform the organ transplant landscape.
Xenotransplantation involves using cells, tissues, or organs from non-human sources to treat human medical conditions. In March 2024, eGenesis successfully performed a porcine kidney transplant in a living patient, a procedure authorized by the U.S. Food & Drug Administration (USFDA).
eGenesis CEO Mike Curtis commented on the investment, noting that Natco’s support will help advance their research and bring their innovative therapies to the market. Natco Pharma, an Indian pharmaceutical company established in 1981, is known for its focus on producing generic medicines and specialty pharmaceuticals.
The company has made significant strides in the development, manufacturing, and marketing of high-quality, affordable medications, particularly in the areas of oncology, cardiology, and hepatology. Natco Pharma has a strong global presence, with operations in India, the United States, and other international markets, and is recognized for its work in launching complex and challenging generic drugs. The company also invests heavily in research and development to bring innovative treatment solutions to patients worldwide, reinforcing its commitment to improving healthcare access.
